retatrutide clinical trial results 2024 2025 press release Headline published this week from TRIUMPH-1 Lilly's triple agonist, retatrutide, demonstrated – Lilly's retatrutide delivers promising results

Gradual and progressive with small victories that are creating great benefits

This study was retained in the DCD analysis due to its rigorous methodology, with its larger sample size (227 participants) and extended 12-month follow-up period likely contributing to the observed differences in effect size

These combined effects have led some clinicians to use GHK-Cu injections in cases like androgenetic alopecia or alopecia areata (as an off-label trial), where conventional treatments are insufficient

At our clinic, we use follow-up blood tests and patient feedback to fine-tune this schedule, ensuring you dont experience an energy crash between appointments